Finally, Gpr43 activation by SCFA in (small) intestinal enteroendocrine L cells induces GLP-1 release that can also affect insulin sensitivity via incretin response [83]
But the direction of travel is clear: the category is contracting, the compliance requirements are tightening, and the platforms that operate with transparent legal architecture - LegitScript verification, disclosed medical group, clear compounding pharmacy structure - are the ones most likely to still be running the same program in twelve months that they're running today
Clinical evidence suggests patients may achieve an additional 510% total body weight loss over 612 months, though individual response varies considerably
Whether your goal is to smash your weight loss goals out of the park, improve your metabolic health, gain confidence, or a combination of all three, our patients share their stories to show you just how possible this is with Wegovy